Acta Med. 2021, 64: 64-69
https://doi.org/10.14712/18059694.2021.12
Α Case of Severe Thyroid Eye Disease Treated with Tocilizumab
References
1. J Ophthalmol 2015; 2015: 249125.
< J, Sabater LA, Bonet-Farriol E, Velázquez-Villoria A, Galofré JC. Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. https://doi.org/10.1155/2015/249125>
<PubMed>
2. Clin Endocrinol (Oxf) 2010; 73(2): 149–52.
L. What to do for moderate-to-severe and active Graves’ orbitopathy if glucocorticoids fail?
3. Cochrane Database Syst Rev 2018; 11: CD012984.
S, Kang S, Salvi M, Ezra DG. Tocilizumab for thyroid eye disease.
4. Eur Thyroid J 2016; 5(1): 9–26.
< L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. https://doi.org/10.1159/000443828>
<PubMed>
5. Eye (Lond) 2019; 33(2): 191–9.
< D, Rossi F. Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy. https://doi.org/10.1038/s41433-018-0315-9>
<PubMed>
6. Am J Ophthalmol 2014; 157(6): 1299–305.
< PN, Ma R, Pickles T, Rootman J, Dolman PJ. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. https://doi.org/10.1016/j.ajo.2014.02.044>
7. J Endocrinol Invest 1991; 14: 853–60.
< C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotheraphy combined with high-dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than orbital radiotherapy alone: results of a prospective study. https://doi.org/10.1007/BF03347943>
8. Am J Ophthalmol 2018; 195: 181–90.
< JV, Gomez-Reino JJ, Maneiro JR, et al. Tocilizumab in Graves Orbitopathy Study Group. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. https://doi.org/10.1016/j.ajo.2018.07.038>
9. Ocul Immunol Inflamm 2020; 28(2): 281–4.
< T, Deschasse C, Bielefeld P. Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves’ Ophthalmopathy, a Report of Three Cases. https://doi.org/10.1080/09273948.2018.1545914>
10. Eur Thyroid J 2016; 5(2): 106–11.
< MF, Demir O, Ersoy RU, et al. Comparison of Early Total Thyroidectomy with Antithyroid Treatment in Patients with Moderate- Severe Graves’ Orbitopathy: A Randomized Prospective Trial. https://doi.org/10.1159/000444796>
<PubMed>
11. Ophthalmic Plast Reconstr Surg 2017; 33(3): e55–e57.
< A, Eliasieh K, Silkiss RZ. Clinical Response to Tocilizumab in Severe Thyroid Eye Disease. https://doi.org/10.1097/IOP.0000000000000730>
12. Am J Surg 2006; 191: 400–5.
< KJ, Solorzano CC, Lee JK, Gaffud MJ, Prinz RA. Thyroidectomy remains an effective treatment option for Graves’ disease. https://doi.org/10.1016/j.amjsurg.2005.10.043>